Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $101,192.97 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 16,671 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $6.07, for a total transaction of $101,192.97. Following the completion of the sale, the insider directly owned 15,353,338 shares of the company’s stock, valued at approximately $93,194,761.66. This represents a 0.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total transaction of $78,348.40.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.08, for a total transaction of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.14, for a total transaction of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total transaction of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.60, for a total transaction of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total transaction of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total transaction of $2,503,901.52.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $5.78 on Monday. The firm has a market cap of $802.96 million, a P/E ratio of -1.45 and a beta of 1.27. The firm has a 50 day simple moving average of $5.16 and a 200 day simple moving average of $5.27. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.38 million. During the same period in the previous year, the business posted ($1.02) earnings per share. Vir Biotechnology’s revenue was down 60.5% compared to the same quarter last year. On average, sell-side analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on VIR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Tuesday, October 14th. Raymond James Financial began coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They issued an “outperform” rating on the stock. Evercore ISI began coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 price target on the stock. Bank of America raised shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research report on Monday, September 15th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.30.

Institutional Investors Weigh In On Vir Biotechnology

Several institutional investors have recently added to or reduced their stakes in VIR. GAMMA Investing LLC lifted its position in Vir Biotechnology by 3,945.6% in the 1st quarter. GAMMA Investing LLC now owns 46,079 shares of the company’s stock valued at $299,000 after acquiring an additional 44,940 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Vir Biotechnology during the 1st quarter worth about $78,000. Principal Financial Group Inc. increased its stake in shares of Vir Biotechnology by 2.7% during the 1st quarter. Principal Financial Group Inc. now owns 459,337 shares of the company’s stock worth $2,977,000 after purchasing an additional 12,024 shares during the last quarter. Cerity Partners LLC acquired a new position in shares of Vir Biotechnology during the 1st quarter worth about $97,000. Finally, CWM LLC increased its stake in shares of Vir Biotechnology by 1,160.2% during the 1st quarter. CWM LLC now owns 17,554 shares of the company’s stock worth $114,000 after purchasing an additional 16,161 shares during the last quarter. 65.32% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).